129 related articles for article (PubMed ID: 14528066)
21. Chemotherapy-induced acral erythema in a pediatric patient with acute monoblastic leukemia.
Demircioğlu F; Oren H; Yilmaz S; Arslansoyu S; Eren S; Irken G
Pediatr Hematol Oncol; 2008; 25(3):211-5. PubMed ID: 18432504
[TBL] [Abstract][Full Text] [Related]
22. [A case report of a patient with hand-foot syndrome induced by bolus 5-fluorouracil therapy].
Matsuyama T; Uetake H; Aoyagi H; Kobayashi H; Ishikawa T; Iida S; Higuchi T; Yasuno M; Enomoto M; Sugihara K
Gan To Kagaku Ryoho; 2008 Nov; 35(12):2147-9. PubMed ID: 19106552
[TBL] [Abstract][Full Text] [Related]
23. Toxicity of dose-dense docetaxel followed by doxorubicin with cyclophosphamide as adjuvant therapy for breast cancer in a phase II study.
Lambert-Falls R; Modugno S
Clin Breast Cancer; 2007 Aug; 7(9):697-704. PubMed ID: 17919350
[TBL] [Abstract][Full Text] [Related]
24. Chemotherapy-induced iatrogenic injury of skin: new drugs and new concepts.
Choi JN
Clin Dermatol; 2011; 29(6):587-601. PubMed ID: 22014981
[TBL] [Abstract][Full Text] [Related]
25. [Main treatment and preventive measures for hand-foot syndrome, a dermatologic side effect of cancer therapy].
Bartal A; Mátrai Z; Szûcs A; Liszkay G
Magy Onkol; 2011 Jun; 55(2):91-8. PubMed ID: 21655474
[TBL] [Abstract][Full Text] [Related]
26. Docetaxel recall phenomenon at the site of previous drug extravasation.
Ley BD; Millán GG; Perez JS; Fraga J; Díez AG
Arch Dermatol; 2010 Oct; 146(10):1190-1. PubMed ID: 20956672
[No Abstract] [Full Text] [Related]
27. Influence of Chemotherapy on the Antioxidant Status of Human Skin.
Lee BN; Jung S; Darvin ME; Eucker J; Kühnhardt D; Sehouli J; Chekerov R; Patzelt A; Fuss H; Yu RX; Lademann J
Anticancer Res; 2016 Aug; 36(8):4089-93. PubMed ID: 27466518
[TBL] [Abstract][Full Text] [Related]
28. Hand-foot and stump syndrome to sorafenib.
Lai SE; Kuzel T; Lacouture ME
J Clin Oncol; 2007 Jan; 25(3):341-3. PubMed ID: 17235051
[No Abstract] [Full Text] [Related]
29. False positive tumor markers: elevation in patients with breast cancer on FAC-type chemotherapy and correlation with the development of hand-foot syndrome.
Tyshler LB; Longton GM; Ellis GK; Livingston RB
Int J Biol Markers; 1996; 11(4):203-6. PubMed ID: 9017443
[TBL] [Abstract][Full Text] [Related]
30. Rash, nephritis, hypertension, and haemolysis in patient on 5-fluorouracil, doxorubicin, and mitomycin-C.
Karlin DA; Stroehlein JR
Lancet; 1980 Sep; 2(8193):534-5. PubMed ID: 6105582
[No Abstract] [Full Text] [Related]
31. Persistent docetaxel-induced supravenous erythematous eruption.
Fernandes Kde A; Felix PA
An Bras Dermatol; 2015; 90(5):728-30. PubMed ID: 26560218
[TBL] [Abstract][Full Text] [Related]
32. Host-vs.-altered-host eruptions in patients on liposomal doxorubicin.
Skelton H; Linstrum J; Smith K
J Cutan Pathol; 2002 Mar; 29(3):148-53. PubMed ID: 11972711
[TBL] [Abstract][Full Text] [Related]
33. Extravasation of docetaxel.
Cifuentes L; Ring J; Brockow K
J Dtsch Dermatol Ges; 2012 Sep; 10(9):662-3. PubMed ID: 22734918
[No Abstract] [Full Text] [Related]
34. [Chemotherapy-induced acral erythema: a clinical and histopathologic study of 44 cases].
Hueso L; Sanmartín O; Nagore E; Botella-Estrada R; Requena C; Llombart B; Serra-Guillén C; Alfaro-Rubio A; Guillén C
Actas Dermosifiliogr; 2008 May; 99(4):281-90. PubMed ID: 18394404
[TBL] [Abstract][Full Text] [Related]
35. Grade 3 liposomal-doxorubicin-induced skin toxicity in a patient following complete resolution of moderately severe sunburn.
Markman M; Kulp B; Peterson G
Gynecol Oncol; 2004 Aug; 94(2):578-80. PubMed ID: 15297208
[TBL] [Abstract][Full Text] [Related]
36. Severe palmoplantar erythrodysesthesia and intertrigolike eruption induced by polyethylene glycol-coated liposomal doxorubicin.
Campanelli A; Kerl K; Lübbe J
J Eur Acad Dermatol Venereol; 2006 Sep; 20(8):1022-4. PubMed ID: 16922969
[No Abstract] [Full Text] [Related]
37. Acute cutaneous reactions to docetaxel, a new chemotherapeutic agent.
Zimmerman GC; Keeling JH; Burris HA; Cook G; Irvin R; Kuhn J; McCollough ML; Von Hoff DD
Arch Dermatol; 1995 Feb; 131(2):202-6. PubMed ID: 7857119
[TBL] [Abstract][Full Text] [Related]
38. Phase 2 trial of liposomal doxorubicin (40 mg/m(2)) in platinum/paclitaxel-refractory ovarian and fallopian tube cancers and primary carcinoma of the peritoneum.
Markman M; Kennedy A; Webster K; Peterson G; Kulp B; Belinson J
Gynecol Oncol; 2000 Sep; 78(3 Pt 1):369-72. PubMed ID: 10985896
[TBL] [Abstract][Full Text] [Related]
39. Prospective study of the cutaneous adverse effects of sorafenib, a novel multikinase inhibitor.
Autier J; Escudier B; Wechsler J; Spatz A; Robert C
Arch Dermatol; 2008 Jul; 144(7):886-92. PubMed ID: 18645140
[TBL] [Abstract][Full Text] [Related]
40. The hand-foot syndrome--a frequent secondary manifestation in antineoplastic chemotherapy.
Janusch M; Fischer M; Marsch WCh; Holzhausen HJ; Kegel T; Helmbold P
Eur J Dermatol; 2006; 16(5):494-9. PubMed ID: 17101468
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
